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Abstract
Rejection is one of the key factors that determine 
the long-term allograft function and survival in renal 
transplant patients. Reliable and timely diagnosis 
is important to treat rejection as early as possible. 
Allograft biopsies are not suitable for continuous 
monitoring of rejection. Thus, there is an unmet 
need for non-invasive methods to diagnose acute 
and chronic rejection. Proteomics in urine and blood 
samples has been explored for this purpose in 29 
studies conducted since 2003. This review describes 
the different proteomic approaches and summarizes 
the results from the studies that examined proteomics 
for the rejection diagnoses. The potential limitations 
and open questions in establishing proteomic markers 
for rejection are discussed, including ongoing trials and 
future challenges to this topic. 
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Core tip: Timely detection and treatment of acute 
and chronic rejection is important to maintain the 
allograft function in renal transplant patients. Allograft 
biopsies are unsuitable for continuous monitoring for 
rejection. This review summarizes the past experience 
with proteomic approaches to diagnose rejection non-
invasively. Potential limitations and open questions 
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in establishing proteomic markers for rejection are 
discussed, including ongoing trials and future challenges 
to this topic. 
Gwinner W, Metzger J, Husi H, Marx D. Proteomics for rejection 
diagnosis in renal transplant patients: Where are we now? World J 
Transplant 2016; 6(1): 28-41  Available from: URL: http://www.
wjgnet.com/2220-3230/full/v6/i1/28.htm  DOI: http://dx.doi.
org/10.5500/wjt.v6.i1.28
INTRODUCTION
Since 2003, proteomics in blood and urine has 
been explored for non-invasive rejection diagnosis 
in renal transplant patients. In this review, we sum-
marize and discuss the approaches and results of 
previous proteomic studies on the background of 
the heterogeneous and complex condition “allograft 
rejection”. Ongoing studies on this topic are reported 
and future challenges in establishing proteomic 
markers for rejection are discussed. 
IMPORTANCE OF REJECTION FOR THE 
LONG-TERM ALLOGRAFT OUTCOME
Despite all improvements in immunosuppressive 
protocols and patient surveillance after kidney 
transplantation, allograft rejection remains a significant 
adverse factor for the long-term allograft survival. In a 
previous study, both T cell-mediated rejection (TCMR) 
and antibody-mediated rejection (ABMR) were reported 
as leading causes of graft failure in a substantial 
proportion of patients[1]. Acute TCMR is most prevalent 
in the first year after transplantation and has been 
suggested as a trigger for subsequent development 
of ABMR[2]. ABMR often evolves over prolonged time 
and may become chronic, with appearance of donor-
specific antibodies first, followed by acute injury of 
peritubular and glomerular capillaries which in the 
later course leads to transplant glomerulopathy and 
tubulointerstitial scarring[3]. Some patients may 
also present with concomitant findings of TCMR and 
ABMR (i.e., mixed rejection)[4]. Consequently, early 
recognition of rejection is important during the entire 
post-transplant course on a continuous basis to treat 
the rejection timely and to adjust the maintenance 
immunosuppression in order to prevent further re-
jection episodes and chronification of the rejection. 
Monitoring for rejection is a challenge and has not 
been satisfactorily solved. Regular measurement of 
serum creatinine or cystatine C to detect declining 
allograft function (which then triggers an allograft 
biopsy) is insensitive and is a late indicator when 
tissue injury has already taken place[5]. Some patients 
may present with increased proteinuria but similar 
to declining graft function, this can only indicate 
established injury and is non-specific as to the cause 
of injury[6]. In the case of ABMR, monitoring for donor 
specific antibodies may identify patients at risk; 
however, in our experience full-blown histopathologic 
features of ABMR can be present without detectable 
antibodies using currently available assays. Many 
transplant centres have turned to protocol biopsies to 
evaluate the course of the allograft. Protocol biopsies 
may give valuable information, e.g., on silent and early 
rejection processes, toxicity of medical treatments, BK 
virus infection and development of chronic scarring 
processes[5]. However, continuous monitoring for 
rejection over the entire post-transplant course would 
require performing biopsies unrealistically often. 
Due to this diagnostic dilemma, there is clearly a 
need for sensitive, non-invasive methods to monitor 
for rejection and to detect rejection at an early stage. 
Such tests could be performed regularly to identify 
those patients who need further workup by an allograft 
biopsy. Several molecules in blood and urine have 
been evaluated (either as a single marker or as a 
combination of markers) based on the hypothesis that 
blood and urine can reflect the molecular processes in 
the allograft. In theory, testing for markers of rejection 
in blood and urine could even outperform the diagnosis 
by biopsy, which is prone to sampling errors and inter-
observer variability. However, none of these tests has 
gained widespread clinical use[5]. 
RATIONALE FOR A MULTI-MARKER 
APPROACH TO DIAGNOSE REJECTION 
Rejection is a heterogeneous process[7-9] and therefore 
it is unlikely that a single marker or small number 
of markers can reflect all facets of rejection reliably. 
Heterogeneity refers to the entities of T cell- and 
antibody-mediated rejection but also to the sites 
of immunological attack and to the morphological 
severity as specified by the Banff classification[7] 
and shown in Figure 1. Also, as a reflection of the 
severity the rejection may be subclinical, i.e., without 
a concomitant decline in allograft function or clinical 
with accompanying graft dysfunction[10]. As outlined in 
Figure 1, rejection is a disease process that extends 
from the activation of the immune system to the 
scarring of injured renal structures. This implies that 
time-dependent features may also be important to 
consider in terms of early and later stages of rejection. 
Given these facts, the hypothesis of multi-marker 
approaches is that a panel of molecules is better suited 
to detect the diverse aspects of rejection than a single 
molecular marker. In fact, gene expression analysis 
of allograft biopsies has demonstrated that different 
types of rejection present with distinct molecular 
phenotypes, containing a wide array of chemokines, 
cytokines and other regulatory molecules[11]. Some of 
these phenotypic signatures should be detectable in 
blood and urine and usable for the rejection diagnosis. 
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It is important to note that the rejection process 
induces host responses like repair and healing me-
chanisms including scarring processes which contribute 
to molecular signatures[12] (Figure 1). On theoretical 
grounds, marker sets for the diagnosis of rejection 
should be distinct from those signatures as they rather 
reflect the sequel of rejection instead of depicting 
specifics of the rejection process itself. As an example, 
urinary β2-microglobulin or fragments of it have been 
reported as potential indicators of rejection[13,14]. 
Further analysis however showed that increased 
urinary β2-microglobuline-derived peptides are similarly 
present in pure cases of acute tubular injury[15] and in 
cases with tubular atrophy and interstitial fibrosis[16,17], 
without any evidence of rejection. 
To date, several approaches have been employed 
to establish multi-marker models for the non-invasive 
diagnosis of rejection. Gene expression, RNA analysis 
and proteomics are the commonest whereas fewer 
studies concentrated on microRNA analysis[18], me-
tabolomics[19] and lipidomics. This review focuses on 
proteomics in blood and urine of kidney transplant 
patients to diagnose rejection. 
PROTEOME ANALYSIS
The proteome is the whole set of proteins present in an 
organism or in one of its functional or structural units 
at a given state. Compared to the transcriptome or 
the metabolome, the proteome is the most functional 
compartment and is subject to continuous and dynamic 
changes either in response to external stimuli or 
alterations in homeostasis[20]. In recent years, clinical 
research mainly focused on the detection of single 
proteins by immunological techniques. This hypothesis-
driven approach requires precedent knowledge on the 
functional characteristics of a specific protein target. 
Proteome analysis in contrast is hypothesis-free 
since it explores a biological sample in its proteomic 
entirety. Therefore, by comparison of the proteomic 
content at two or more distinct conditions (e.g., 
diseased and non-diseased) all differently expressed 
proteins may be captured as potential differentiating 
markers. Technically, proteomic technologies rely on 
the physicochemical properties of the proteins instead 
of immunological properties, which are required for 
antibody-mediated analyte detection. 
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Figure 1  Kidney allograft rejection types, histological sites of injury and underlying mechanisms. TCMR includes recognition and presentation of donor 
antigens by antigen-presenting cells to T cells, which become activated and undergo proliferation. Activated T-cells invade vascular, tubular and interstitial structures. 
Vascular rejection often presents with some degree of tubulointerstitial inflammation; however pure cases of vascular rejection (“v-only”) can be observed[8]. In ABMR, 
activated T cells induce B cells to undergo plasma cell proliferation resulting in the production of donor-specific antibodies. Antibody-mediated injury to pre-glomerular 
arteries, glomerular and peritubular capillaries is mediated by local activation of complement factors however, non-complement-fixing antibodies may also play a 
role in some cases[9]. Isolated findings of glomerular and peritubular capillaritis or pre-glomerular arteritis may be present or a combination of these features[7]. TCMR 
and ABMR can occur simultaneously (i.e., mixed rejection)[4]. The rejection processes can lead to different histological forms of injury and if not successfully treated, 
to scarring. The Banff classification[7] associates the elementary lesions of glomerular (g) and peritubular capillaries (ptc) and pre-glomerular vessels (v) to ABMR. 
TCMR includes tubulointerstitial infiltration (Borderline, Ⅰ) and arteritis of pre-glomerular vessels (Ⅱ-Ⅲ). Banff grades (a-b, Ⅱ-Ⅲ, v1-3, g1-3, ptc1-3) denote different 
severities of the lesions. TCMR: T cell-mediated rejection; ABMR: Antibody-mediated rejection. 
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that proteins and peptides are transferred into ions, 
which are then subjected to an electric or magnetic 
field. The subsequent characterization of each ion is 
based on its mass over charge ratio (m/z). Electron 
spray ionization, matrix-assisted laser desorption/
ionization and surface enhanced laser desorption-
ionization are the main ionization techniques used in 
clinical proteomic studies. 
Protein mass detection: The desolvatized ions in 
the electric or magnetic field are then collected by the 
mass detector. Many different concepts exist, mostly 
in respect to how an ionic signal is amplified. “Time of 
flight”, Orbitrap and Triple Quadrupoles are the most 
commonly used detectors in biomarker research. 
Protein quantification 
Normally, only relative quantification is possible with 
mass spectrometry (MS) techniques, based on an 
approximate proportionality between signal intensity 
and the relative protein/peptide abundance in a sample. 
Advanced methods have been developed like “isobaric 
tags for relative and absolute quantification”[24]. And 
“multiple reaction monitoring”[25] to compare the 
protein/peptide abundance between different samples. 
Protein sequence identification
In its simple one-dimensional form, mass spectrome-
try gives mass over charge ratios of peptides and 
proteins but no information on the amino acid se-
quence. This may be sufficient to identify and detect 
proteomic markers for disease conditions simply by 
their physicochemical characteristics. Nevertheless, 
identification of the proteins and peptides may be 
desirable, e.g., to understand pathophysiologic 
pathways or to transfer the discovered markers to 
another platform (e.g., ELISA). With tandem mass 
spectrometry (MS/MS), a MS-detected peptide can 
be isolated in the first MS dimension and then forced 
into multiple rounds of collisions in the second MS 
dimension to generate an ordered fragment ion 
spectrum[26].
Construction of multi-marker diagnostic models 
Although average levels of single proteins or peptides 
may be significantly different between case and control 
groups large overlap of values is often observed when 
individual samples are compared with each other[27]. 
To construct classifiers with as little overlap as possible 
between case and control groups, biomarkers are 
often combined into multi-marker sets[28]. This strategy 
can compensate for analytical variances and biological 
variability like heterogeneity of the disease process, 
time-dependent changes, or confounding conditions. 
The integration of proteins/peptides into a multi-
marker set can range from a few individual molecules 
up to whole “fingerprints” (chromatograms, spectra), 
depending on the requirements for sensitivity and 
Biomarker research by proteomics is based on the 
hypothesis that at least one of the following conditions 
is true: (1) Proteins are differentially expressed from 
their genes during a disease process; (2) Proteins are 
subject to differential post-translational modifications 
due to disease-specific changes in the activity of 
enzymes; and (3) Proteins are detectable in different 
amounts due to altered production, degradation or 
release from cells by the disease process. 
Sample matrix
In biomarker research, easily accessible sample matrices 
like blood or urine are preferred because procurement 
of tissue relies on invasive methods. Blood has a high 
dynamic range of protein concentrations, necessitating 
depletion of the most abundant proteins to improve 
detection of low abundant protein markers. It is also 
characterized by lower stability due to high proteolytic 
activity. Urine on the other hand, has a higher stability 
and lower complexity than blood. However, urine is in 
contact with the genital-urinary tract and thus, prone 
to bacterial contamination. Moreover, the proteomic 
compounds in urine originate from different sources, 
namely from the systemic circulation via glomerular 
filtration, from the kidney, and from the urinary tract. 
The exact contribution by these sources is unknown and 
may change in disease conditions. 
Proteomic workflow
The proteomic workflow includes the preparation 
of the sample to clear the proteomic content from 
other compounds, followed by complexity-reducing 
separation and physicochemical detection methods.
Sample preparation: Before proteomic analysis, a 
sample usually needs processing to remove insoluble 
materials like cell debris and interfering salt and lipids. 
It is however important to note that such preparation 
steps introduce bias and add variability, and therefore 
should be restricted to the absolute requirements[21]. 
Because proteins can be degraded by proteases, heat, 
bacteria and pH changes, the integrity of the samples 
should be maintained by applying standardized 
collection protocols and immediate freezing. 
Protein separation: Historically, 2-D gel electro-
phoresis used to be the principal proteomic separation 
method[22]. This is now largely replaced by the non-
gel based separation methods liquid chromatography 
(LC) and capillary electrophoresis (CE), which have 
a higher resolving capacity. Using LC and CE, small 
proteins and peptides can be directly subjected to 
mass spectrometry analysis whereas larger proteins 
have to be cleaved by trypsin before separation and 
mass detection[23].
Protein ionization: There are many different mass 
spectrometry methods but they all have in common 
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specificity and on the complexity of the disease of 
interest. 
Methods to integrate multiple discriminative 
proteins into a biomarker model can be divided into 
“linear” and “high dimensional” algorithms, the latter 
tending to have better results due to a weighted 
combination of the markers according to the degree 
of their correlation. Here, the most frequently used 
algorithms are “support vector machine”, adaptive 
boosting, random forest and neural networks.
PROTEOMIC STUDIES ON RENAL 
ALLOGRAFT REJECTION 
The literature search was done in PubMed using the 
keywords “kidney, rejection, proteomics, urine mass 
spectrometry, allograft, peptidomics, chronic allograft 
nephropathy” in different combinations (Figure 2). 
Of the 158 publications, 111 were excluded after 
reviewing title and abstract of each publication. The 
remaining 47 articles were kept for in depth study. 
Ten articles were excluded because they concentrated 
only on technical aspects (n = 4), did not use shotgun 
proteomic methods (n = 5), or did not examine 
rejection patients (n = 1). 
Examination of patients with chronic rejection/
chronic allograft nephropathy was reported in 
eight studies[16,17,29-34]. However, evaluation of the 
histomorphological reporting revealed that patients 
in these studies had merely interstitial fibrosis and 
tubular atrophy (IFTA; Banff category 5) according 
to the latest update of the Banff classification[7], 
without any evidence of acute or chronic rejection. 
This mistaking is explained by the historical definition 
of “chronic allograft nephropathy”, which does not 
differentiate between patients with non-specific chronic 
lesions (IFTA) and patients with signs of chronic 
rejection. Hence, these studies were considered as 
non-relevant for the topic “rejection” and excluded 
from the reporting in Table 1. 
The remaining 29 studies[13-15,35-60] are listed in 
Table 1. Five studies reported a prospective study 
design[37,41,45,46,57], with assumable random or conse-
cutive sample selection. In the remaining studies, 
samples seemed to be drawn from a biobank/sample 
archive not specifically established for the proteome 
study, without giving details to selection process 
and randomness of the samples. Most studies were 
cross-sectional. Nine studies described longitudinal 
aspects with regard to sample collection[39], profiling 
of sequential samples or comparison of proteome 
patterns before and after rejection[13,35,37,41,45,53,60] and 
to the assessment of graft survival[59]. 
One third of the study performed proteomic analysis 
on an independent validation set of samples to confirm 
the discovered markers. Validation on independent 
samples was also performed by ELISA assays for the 
discovered markers[50,51,53,60]. 
Urine was clearly the diagnostic matrix of choice, 
with 23 studies compared to the six studies that 
examined blood samples. In the study of Ling et al[40] 
mRNA expression in biopsies was examined in parallel 
to the urinary proteome. O’Riordan et al[45] stained 
biopsies to confirm the identified urinary proteomic 
marker β-defensin-1. 
In approximately half of the studies, patients with 
TCMR were examined, as evident from the reported 
Banff grades. Patients with ABMR were included in six 
studies[35,47,48,51,58]; in one study[46] a few patients were 
reported to have mixed rejection (TCMR + ABMR). In 
Figure 2  Search strategy for proteomic studies in the field of renal allograft rejection. IFTA: Interstitial fibrosis and tubular atrophy.
June 2015 PubMed search for: (kidney rejection proteomics) and/or (urine rejection 
proteomics) and/or (kidney rejection mass spectrometry) and/or (kidney allograft 
peptidomics) and/or (proteomics chronic allograft nephropathy) 
n  = 158 articles
Metabolomics, Transcriptomics and drug 
monitoring studies: n  = 55
Reviews, editorials, case-reports, animal studies: n  = 37
Technological/bioinformatics articles: n  = 3
ELISA, assay-based methods: n  = 8
Other transplantation associated complications: n  =  4
Not in English, meeting reports: n  = 4
n  = 47 articles kept for in depth reading
n  = 29 articles kept for review
IFTA without evidence for 
chronic rejection: n  = 8
Other topic, other platforms: n  = 10
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Table 1  Proteomic studies on renal allograft rejection
Ref. B/U Training 
set
n Validation 
set
n Proteomic 
method
Performance Identified molecules Remarks
Akkina et al[35] U C (bx) 13 None iTRAQ- NR None Study included healthy 
individuals.
Study concentrates on longitudinal 
stability of peptides in rejecting 
and non-rejecting patients
BL   1 MALDI-
Ⅱa   1 MS/MS
aABMR   1
Clarke et al[36] U C (st) 15 None SELDI- Accuracy 91% 
Sensitivity 83% 
Specificity 100%
(2-marker classifier)
None 
AR 15 TOF-MS
Freue et al[37] B C (bx) 21 None iTRAQ- AUC 0.86
Sensitivity 80% 
specificity 90%
(4-marker classifier)
Up-regulated: TTN, 
LBP, PI16, CFD, MBL2, 
SERPINA10, B2M 
Down-regulated: 
KNG1, AFM, 
SERPINA5, LCAT, 
SHBG
ELISA was performed on 4 of the 
identified markers (coagulation 
factor IX, SHBG, CFD, LCAT) in 
blood
Ⅰa   7 MALDI-
Ⅰb   1 MS/MS
Ⅱa   3
Günther 
et al[38]
B C (st) 13 C (st)   7 iTRAQ- AUC 0.76 21 peptides Different statistical approaches 
to integrate proteomics and 
transcriptomic results are presented
AR 13 AR   7 MALDI- Sensitivity 57% 
MS/MS specificity 86%
Jahnukainen 
et al[39]
U C (st) 29 None SELDI- Sensitivity 81% 
Specificity 84%
(100-marker 
classifier)
None 21 of the 28 rejection samples 
showed also signs of chronic 
rejection 
Article concentrates on 
differentiation of AR and BKV-NP
Ⅰa-Ⅱb 28 TOF-MS
BKV 21
Ling et al[40] U C (bx) 10 C (bx) 10 LC-MALDI- AUC 0.96
(40-marker 
classifier)
COL1A2, COL3A1, 
UMOD, MMP-7, 
SERPING1, TIMP1
Study included healthy individuals 
and patients with native kidney 
disease (nephrotic syndrome). 
Results of proteomic analysis 
are related to mRNA expression 
profiling of corresponding biopsies
AR 10 AR 10 TOF-MS
BKV 10 BKV   4 LC-MS/MS
Loftheim 
et al[41]
U C (st)   6 None 2D LC- NR Up-regulated: 
IGFBP7, VASN, EGF, 
LGALS3BP
Study collected sequential urines 
from the beginning after Tx. 
Analysed samples for rejection 
patterns were taken 7-11 d before 
biopsy
BL   1 MS/MS
Ⅰa   4
Ⅱa   1
Mao et al[42] U C (bx) 22 C (bx) 14 SELDI- Sensitivity 90% 
Specificity 71%
(4-marker classifier)
None All TCMR cases were subclinical 
rejections with grades ≥ ⅠaTCMR 27 TCMR 10 TOF-MS
Metzger 
et al[43]
U C (bx) 23 C (bx) 36 CE-MS AUC 0.91
Sensitivity 93% 
Specificity 78%
(14-marker 
classifier)
3 fragments of 
COL1A1,
1 fragment of COL3A1
Rejections in the training set were 
all subclinical. The validation 
set contained 10 clinical and 
18 subclinical rejection cases. 
Confounder like ATI in biopsies, 
urinary tract infection and CMV 
infection were considered
Ⅰa 13 Ⅰa 23 LC-MS/MS
Ⅰb   3 Ⅰb   5
O’Riordan 
et al[44]
U C (st) 22 None SELDI- AUC 0.91
Sensitivity 91%
Specificity 77%
(2-marker classifier)
Up-regulated: 
SERPINA3
Downregulated: 
DEFB1
Study included healthy individuals
AR 23 TOF-MS
O’Riordan 
et al[45]
U C (st) 22 None SELDI- AUC 0.91
Sensitivity 91%
Specificity 77%
(2-marker classifier)
Up-regulated: 
SERPINA3
Downregulated: 
DEFB1
BL   3 TOF MS
Ⅰa   6 LC-MS/MS
Ⅰb   4
Ⅱa   7
Ⅱb   3
Pisitkun 
et al[46]
U C (bx)   2 None LC-MS/MS NR Numerous molecules
Ⅰa   4
Ⅰb   1
Ⅱa   2
ATI   7
Quintana 
et al[47]
U C (st)   8 a/cABMR   8 MALDI- IFTA vs cABMR
AUC 1.0
Sensitivity 100%
Specificity 100%
(6-marker classifier)
None Study included healthy individuals
a/cABMR 10 IFTA   6 TOF-MS
IFTA   8
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Quintana 
et al[48]
U C (st)   5 C (st)   9 LC-MS/MS C vs IFTA/ABMR: 
AUC 0.82
IFTA vs ABMR
100% correct IFTA, 
90% correct ABMR
(2-markers) 
Down-regulated: 
UMOD
Differentiation 
between controls and 
IFTA/ABMR: KNG1 
Study included healthy individuals
Two unidentified peptides could 
differentiate between IFTA and 
ABMR, based on quantitative 
differences of the peptides (higher 
in ABMR)
a/cABMR 10 a/cABMR 11
IFTA   8 IFTA   8
Reichelt 
et al[49]
U C (bx) 10 None SELDI- SAX2 protein chip:
Sensitivity 90% 
Specificity 80%
CM10 protein chip:
Sensitivity 92% 
Specificity 85%
(2-marker classifier)
None 
Ⅰa   7 TOF-MS
Ⅰb   3
Ⅱa   1
Ⅱb   2
Schaub et al[13] U C (bx) 22 None SELDI- Sensitivity 94% 
Specificity 82%
(3-marker classifier)
Cleaved B2M
Cleaved B2M
Study included healthy 
individuals. 
The clinical confounder CMV 
viremia was assessed. 
Longitudinal evaluation of urine 
proteome patterns differentiated 
between patients with stable course 
and rejection
Ⅰa   7 TOF-MS
Ⅰb   8
Ⅱa   3
ATI   5
GL   5
Schaub et al[15] U C (bx) 22 None SELDI- NR Study included healthy 
individuals. 
Study concentrated on cleavage 
mechanisms for b2-microglobulin
Ⅰa   7 TOF-MS,
Ⅰb   8 LC-MALDI-
Ⅱa   3 MS
ATI   5
GL   5
Sigdel et al[14] U C (bx) 10 None LC-MALDI- NR List of 73 candidates, 
incl. fragments of 
collagens, UMOD, 
B2M, PTGDS
Study included healthy individuals
AR 10 MS/MS
Sigdel et al[50] U C (bx) 10 None LC-MS/MS AUC 0.84-0.97
for 3 single 
molecules 
(by ELISA)
Upregulated: 
SERPINF1 
Down-regulated: 
UMOD, CD44
Study included healthy individuals 
and patients with native kidney 
disease (proteinuria)
AR 10
Sigdel et al[51] U C (bx) 30 None iTRAQ- AUC 0.8
for 3 single
molecules
(by ELISA)
HLA-DRB1, KRT14, 
HIST1H4B, FGG, 
ACTB, FGB, FGA, 
KRT7, DPP4, cleaved 
B2M
In ELISA studies, FGG could 
also segregate AR from BKV-
nephropathy
Validation set for detection of 
FGG, HLA DRB1, FGB by ELISA 
included 44 stable transplant 
patients and 44 patients with 
rejection
Ⅰa-Ⅱb 30 LC-MS/MS
aABMR   2
IFTA 30
BKV 18
Sigdel et al[52] U C (bx) 20 None iTRAQ- NR Enriched in exosomal 
fraction in AR: A2M, 
APOA2, APOM, CD5L, 
CLCA1, FGA, FGB, 
IGHM, DEFA5, PROS1, 
KIAA0753
Exclusively in the 
exosomal fraction in 
AR: CLCA1, PROS1, 
KIAA0753
Study concentrated on differences 
between the whole proteome in 
urine (non-fractionated) and the 
exosomal fraction
≥ Ⅰa 20 LC-MS/MS
Stubendorff 
et al[53]
U C (st) 16 C (st) 16 SELDI- Sensitivity 94% 
Specificity 44% 
(4-marker classifier)
Sensitivity 80%
Specificity 81%
for 2 molecules
(by ELISA)
Up-regulated: A1MG, 
HP
Results on longitudinally collected 
samples suggest that alpha-1-
microglobulin and haptoglobin 
indicate upcoming AR early
AR 16 AR 16 TOF MS
Sui et al[54] B C (bx) 12 None MALDI- Recognition 
capability for 
AR 90% 
None Study included healthy individuals. 
Sample clean-up was performed 
with magnetic beads
AR 12 TOF-MS
CR 12
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the remaining studies, no clear Banff descriptors were 
provided leaving it open whether TCMR or ABMR was 
present and which severity grades and subtypes of 
rejection were observed. Apparently, almost all studies 
concentrated on acute rejection. Cases with chronic 
TCMR were included in the study of Jahnukainen et 
al[39], patients with chronic active ABMR were reported 
by Quintana et al[47,48]. One study examined chronic 
rejection without detailed scoring with regard to TCMR 
and ABMR[59]. 
In any proteomic marker discovery study the 
selection of appropriate comparators (controls) is an 
Wang et al[55] B C (bx) 19 C (bx) 10 SELDI- C vs subclinical ≥ Ⅰ
a
Sensitivity 100%
Specificity 90%
(3-marker classifier)
C vs TCMR
Sensitivity 90%
Specificity 90% 
(7-marker classifier)
AR vs subclinical 
Sensitivity 100% 
Specificity 100%
(4-marker classifier)
None ≥ Ⅰa refers to subclinical rejections 
only. 
All (non-graded) TCMR cases were 
clinical rejections
≥ Ⅰa 14 ≥ Ⅰa 10 TOF-MS
TCMR 28
ATI 10
Wittke et al[56] U C (bx) 29 C (bx) 10 CE-MS, Sensitivity 67% 
Specificity 80%
(17-marker 
classifier)
COL4A5 Transplant patients with urinary 
tract infection were included, 
with biopsy-confirmed absence of 
rejection. 
Of the rejection cases, 13 were 
subclinical and 6 clinical
Ⅰa 11 Ⅰa   6 LC-MS/MS
Ⅰb   6 Ⅰb   3
Ⅱa   1
Ⅱb   1 UTI   7
UTI 10
Wu et al[57] B C (st)   8 None iTRAQ- NR Numerous molecules 
belonging to 
different pathways: 
e.g., inflammatory 
response, complement, 
defence response, 
protein maturation and 
processing, humoral 
immune response
Ⅰb   1 2D LC-
Ⅱa   2 MS/MS
Ⅱb   1
Ⅲ   1
Yang et al[58] U C (bx) 36 C (bx) 14 SELDI- C vs
TCMR/ABMR 
Sensitivity 100% 
Specificity 78%
(3-marker classifier)
ABMR vs TCMR 
Sensitivity 80% 
Specificity 95%
(5-marker classifier) 
None
TCMR 30 TCMR 10 TOF-MS
aABMR 25 aABMR 10
ATI 10
Zhang et al[59] U C (bx) 41 None MALDI- Different 
classifier 
combinations:
Sensitivity 73%-88% 
Specificity 53%-62%
Up-regulated: B2M, 
SERPINA1. 
Down-regulated: PSAP
Study included healthy individuals 
and patients with native kidney 
disease (nephrotic syndrome). 
Saposin B was high in transplant 
patients with stable course over 
280 d and low in patients with 
subsequent graft failure
CR/(AR) 90 TOF-MS 
MALDI-
MS/MS
Ziegler et al[60] B C 48 None SELDI- Sensitivity 100%
Specificity 94%
for 2 molecules
(by ELISA)
Out of 22 candidates 
decreased: APOA1, 
SERPINA3
Two patients with TCMR had also 
signs of additional ABMR. 
The 2 markers for rejection were 
not informative in samples 
collected a few days before the 
rejection
Ⅰa 10 TOF-MS 
Ⅰb   7 MALDI-
MS/MS
Patient group definitions: C (bx): Control patients with biopsy-confirmed absence of rejection; C (st): Control patients without biopsy to exclude 
rejection; AR: Acute rejection without further histologic grading; CR: Chronic rejection without further histologic grading; TCMR: T cell-mediated 
without further histologic grading; ABMR: Antibody-mediated rejection with prefix “a” (acute) and “c” (chronic); BL: Borderline rejection (suspicious 
for rejection); IFTA: Interstitial fibrosis and tubular atrophy; BKV: BK virus nephropathy; ATI: Acute tubular injury; GL: De novo or recurrent 
glomerulopathy; UTI: Urinary tract infection with biopsy-confirmed absence of rejection; Ⅰa, Ⅰb: T cell-mediated tubulointerstitial (rejection specified 
as “mild” (a) and “severe” (b); Ⅱa, Ⅱb: T cell-mediated vascular rejection specified as “mild” (a) and “severe” (b); Ⅲ: T cell-mediated vascular rejection 
with transmural arteritis; CMV: Cytomegalovirus; AUC: Area under the curve; CE: Capillary electrophoresis; iTRAQ: Isobaric Tags for Relative and 
Absolute Quantification; LC: Liquid chromatography; MALDI: Matrix-assisted laser desorption ionization; MS: Mass spectrometry; MS/MS: Tandem 
mass spectrometry; SELDI: Surface-enhanced laser desorption ionization; TOF: Time of flight; B/U: Examined matrix (blood: B, urine: U); n: Number of 
patients in each category; NR: Not reported. 
Gwinner W et al . Proteomics for kidney transplant rejection diagnosis
36 March 24, 2016|Volume 6|Issue 1|WJT|www.wjgnet.com
important issue because definition of proteome patterns 
specific for the disease condition - in this case rejection 
- is deduced by comparison to samples without the 
disease condition. Thirteen studies used samples from 
clinically stable transplant patients without confirming 
absence of rejection by biopsy. This implies that these 
patients could have had subclinical rejection (i.e., typical 
histological rejection findings without concomitant 
impaired allograft function). It has been shown that 
subclinical rejection produces proteomic patterns which 
are similar to clinical rejection and three studies have 
examined subclinical TCMR so far[42,43,56]. 
Another important point to consider is the de-
limitation of confounding conditions. For example, 
it is well known that acute tubular injury is present 
in a substantial proportion of patients with acute 
rejection[43]. If no measures are taken to differentiate 
the proteomic signature of rejection from acute tubular 
injury, the proteomic profile for rejection might lack 
specificity as tubular injury is a non-specific finding 
which is also related to drug-toxicity and ischemic/
reperfusion injury. In fact, some of the studies included 
control samples with acute tubular injury[13,15,46,55,58]. 
Likewise, infection could be a confounder, as inflam-
matory pathways are activated in both, infection 
and rejection. To this end, BK virus nephropathy, 
urinary tract infection and CMV have been taken into 
account in some studies[13,39,43,51]. Another important 
confounder may be concurrent IFTA present in biopsies 
with ABMR as compared to biopsies showing IFTA 
without rejection which was addressed in the studies 
from Quintana et al[47,48]. 
Sample size numbers varied considerably in the 
studies, with two to ninety rejection samples for the 
trainings set, and with seven to twenty-eight for the 
validation of the discovered proteomic markers. There 
is certainly no simple rule of thumb to determine the 
necessary sample size. As discussed in the second 
chapter, rejection is a heterogeneous condition. Vari-
ability can probably be reduced by applying stringent 
histomorphological and clinical criteria to define 
the disease condition, nevertheless training sets for 
rejection should be large enough to cover the whole 
spectrum of the rejection type studied. In addition, 
controls/comparator groups without rejection should 
be of sufficient size to cover the whole spectrum of 
confounding conditions. Eventually, measures like area 
under the curve (AUC), sensitivity, specificity, negative 
and positive predictive values will give information 
about the performance of the defined marker set for 
rejection. Some of the studies reported exceptionally 
optimistic performance values, however, performance 
derived from cross-validation within the training set 
inherently carries overfitting of proteomics data and 
validation with external samples can correct for this 
limitation. 
Various molecules have been discovered in the 
different studies and only a few were independently 
reported by different research groups, like frag-
ments of collagens, β2-microglobulin, alpha-1-anti-
chymotrypsin and uromodulin. The large variability 
in the reported markers for rejection is probably 
not primarily related to differences in the rejection 
characteristics of the examined patients. As outlined 
in chapter Ⅲ, “proteome analysis”, the use of different 
MS methods will inevitably result in capturing diverse 
peptides and proteins. This issue is certainly relevant 
once efforts are undertaken to implement such tests 
into the clinical routine. 
An important aspect is the biological significance 
of the identified molecules and the identification of the 
modulated processes which are involved. Combining 
all proteins from the studies mentioned above resul-
ted in eighty-nine non-redundant molecules. These 
were subjected to a systematic analysis of biological 
contextualization using the pathway- and enzyme 
reaction-related Reactome information resource 
(Figure 3). Based on the known molecular associations 
a physical interaction graph was constructed (Figure 
4). The analyses were performed without prior 
knowledge of disease areas or other information that 
might lead to bias. Reactome analysis using ClueGO 
(PMID: 19237447) showed processes related to 
platelet degranulation, keratan sulfate degradation, 
lipid digestion, mobilization and transport, antigen 
presentation and interferon gamma signalling to be 
directly associated with the input proteins. If the 
molecules involved worked in a synchronized manner 
some degree of physical association should be 
expected. To test this, the proteins were clustered using 
MiMI (PMID: 18812364), which connects molecules 
based on prior knowledge observed in other studies 
such as protein-protein interactions. This analysis 
allows expanding the molecular network to connect a 
maximum number of input proteins using gap-filling, 
or bridging, proteins. What is evident from the analysis 
(Figure 4) is that indeed a majority of molecules form 
a large network that is bound together by an additional 
35 entries, which can serve as an entry point for 
further investigations. To this end, several of these 
gene ontology pathways have also been deduced 
from microarray analysis of transplant biopsies with 
rejection[61]. 
CONCLUSION
In summary, the studies published so far convincingly 
show that proteomics is capable of discovering 
molecular mechanisms of renal allograft rejection 
and of defining molecular markers which can aid to 
detect rejection early and reliably. To bring proteomics 
further forward into clinical application in kidney 
transplantation the limitations of previous studies 
should be used as challenges for future trials in the 
discovery and/or validation of rejection markers. Points 
to consider include but are not limited to: 
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Study design: (1) Sufficient number of patients 
with biopsy-confirmed absence of rejection, repre-
senting the whole spectrum of transplanted patients; 
(2) Rigorous histological and serological classification 
of patients with rejection, with a sufficient number 
of cases for each rejection type; (3) Inclusion of 
important and frequent confounding conditions which 
may be concurrently present in patients with and 
without rejection (either in the biopsy or clinically); 
and (4) Besides validation on selected samples as done 
so far in some studies, prospective in-place validation 
under everyday clinical conditions to determine the 
practical value of non-invasive tests for rejection.
Endpoints: (1) Emphasis on early markers which 
can detect incipient, subclinical stages of rejection 
(this will require longitudinal sample collections); (2) 
Development of markers which can indicate response 
to the rejection therapy (this will require longitudinal 
observation); and (3) Prospective, randomized studies 
with and without non-invasive monitoring to determine 
the costs and benefits.
Technical aspects: (1) Uniform sample collection 
protocols, sample preparation and analyses, especially 
if proteomic markers should find wide application; (2) 
Development of simplified test systems which can be 
applied outside highly specialized laboratories (provided 
the number of proteomic markers is not too high); (3) 
Reliable measures for the test system (AUC, sensitivity, 
specificity, negative and positive predictive values, 
thresholds of the test), all derived from independent 
validation studies and measures for reproducibility/
variability; and (4) Identification of confounders that 
reduce the sensitivity or specificity of the proteome 
markers.
Figure 3  Reactome graph, showing the functional association of renal allograft rejection molecules. Literature-derived proteins associated with acute and 
chronic rejection (n = 89, concatenated from the proteomic studies listed in Table 1) were analyzed by functional Reactome group-clustering using CytoScape’s ClueGO 
plug-in (CytoScape v2.8.3, ClueGO v1.5). Enriched Reactome-terms are represented as circles, and lines denote the relationship between these terms as functional 
groups. Line thickness and font-size are directly correlated with the statistical significance of terms and relationships (all with P < 0.05 after Bonferroni-adjustment for 
multiple testing correction). MAPK: Mitogen-activated protein kinase; GRB2: Growth factor receptor-bound protein 2; NCAM: Neural cell adhesion molecule.
Degradation of
the extracellular
matrix
Platelet adhesion
to exposed
collagen
Activation of
matrix
metalloproteinases
Extracellular
matrix
organization
GPVI-mediated
activation
cascade
NCAM signaling
for neurite
out-growth
Collagen
formation
Integrin cell
surface
interactions
GRB2: SOS
provides linkage
to MAPK
signaling for
intergrins
p130Cas linkage
to MAPK
signaling for
integrins
Platelet
aggregation (plug
formation) Integrin alphallb
beta3 signaling
Platelet
activation,
signaling and
aggregation Response to 
elevated platelet
cytosolic Ca2+
Intrinsic
pathway
Formation of
fibrin clot
(clotting
cascade)
Transport of gamma-carboxylated
protein precursors from the
endoplasmic reticulum to the golgi
apparatus
PTM: Gamma carboxylation,
hypusine formation and arylsulfatase
activation
Complement
cascade
Initial triggering of
complement
Removal of
aminoterminal
propeptides from
gamma-carboxylated
proteins
Gamma-carboxylation,
transport, and
amino-terminal
cleavage of
proteins
Cell surface
interactions at the
vascular wall
NCAM1
interactions
Gamma-carboxylation
of protein
precursors
Collagen
biosynthesis and
modifying
enzymes
Common pathway
Glycosphingolipid
metabolism
Keratan
sulfate/keratin
metabolism
HDL-mediated
lipid transport
Lipoprotein
metabolism
Glycosaminoglycan
metabolism
Keratan sulfate
biosynthesis
Keratan 
sulfate
degradation
Lipid
digestion,
mobilization,
and
transport
Interferon
gamma
signaling
Antigen
presentation:
folding,
assembly
and
peptide
loading
of class Ⅰ
MHC
Platelet
degranulation
Gwinner W et al . Proteomics for kidney transplant rejection diagnosis
38 March 24, 2016|Volume 6|Issue 1|WJT|www.wjgnet.com
Figure 4  Expanded molecular interaction model. Physical interaction representation of molecules involved in renal allograft rejection. The concatenated list of 
literature-derived proteins associated with acute and chronic rejection was subjected to interactome-mapping using CytoScape’s Michigan Molecular Interactor (MiMI) 
plug-in (CytoScape v2.8.2, MiMI v3.1). Known protein-protein interactions with up to two additional bridging molecules to maximize the interconnectivity were used 
to generate the map shown, which contains 68 of the 89 differentially expressed molecules and 35 additional bridging proteins. Input molecules are depicted as 
rectangles, and bridging molecules as circles. Each line between proteins represents a direct known association. Included literature-derived proteins associated with 
acute and chronic renal allograft rejection in the network (Rectangles; Green: Down-regulated; Red: Up-regulated; n = 68); Included additional bridging proteins for 
maximum interconnectivity (circles; n = 35); Excluded literature-derived proteins associated with acute and chronic renal allograft rejection not connected to the network 
(not shown; n = 21). A2M: Alpha-2-macroglobulin; ACAN: Aggrecan core protein; ACTB: Actin, cytoplasmic 1; AGT: Angiotensinogen; AMBP: Alpha-1-microglobulin; 
APOA1: Apolipoprotein A1; APOA2: Apolipoprotein A-2; APOM: Apolipoprotein M; B2M: Beta-2-microglobulin; BCAN: Brevican core protein; CALR: Calreticulin-3; 
CD27: CD27 antigen; CFD: Complement factor D; COL1A1: Collagen alpha-1(Ⅰ) chain; COL1A2: Collagen alpha-2(Ⅰ) chain; COL3A1: Collagen alpha-1(Ⅲ) 
chain; CTSZ: Cathepsin Z; DAG1: Dystroglycan; DEFA5: Defensin-5; DEFB1: β-defensin 1; DPP4: Dipeptidyl peptidase 4; EGF: Pro-epidermal growth factor; F2: 
Prothrombin; FABP4: Fatty acid-binding protein, adipocyte; FBXL19: F-box/LRR-repeat protein 19; FGA: Fibrinogen alpha chain; FGB: Fibrinogen beta chain; FGG: 
Fibrinogen gamma chain; FKBP1A: Peptidyl-prolyl cis-trans isomerase FKBP1A; HIST1H4B: Histone H4; HLA-DRB1: HLA-DRB1 protein; HP: Haptoglobin; HTRA1: 
Serine protease HTRA1; IGFBP7: Insulin-like growth factor-binding protein 7; IGHM: Ig mu chain C region; KITLG: Kit ligand; KNG1: Kininogen-1; KRT: Keratin, type Ⅱ 
cytoskeletal; KRT9: Keratin, type I cytoskeletal 9; LBP: LPS-binding protein; LCAT: Phosphatidylcholine-sterol acyltransferase; LGALS3BP: Galectin-3-binding protein; 
LMAN2: Vesicular integral-membrane protein VIP36; LRG1: Leucine-rich alpha-2-glycoprotein; LUM: Lumican; PROS1: Vitamin K-dependent protein S; PSAP: Saposin 
B; SELL: L-selectin; SERPINA1: Alpha-1-antitrypsin; SERPINA10: Protein Z-dependent protease; SERPINA3: Alpha-1-anti-chymotrypsin; SERPINA5: Serine protease 
inhibitor; SERPINF1: Pigment epithelium-derived factor; SERPING1: Plasma protease C1 inhibitor; SHBG: Sex hormone-binding globulin; SUMO2: Small ubiquitin-
related modifier 2; SUSD2: Sushi domain-containing protein 2; TIMP1: Metalloproteinase inhibitor 1; TTN: Titin; UMOD: Uromodulin; VGF: Neurosecretory protein VGF; 
CMA1: Chymase; CXCL10: C-X-C motif chemokine 10; DSTN: Destrin; ENAM: Enamelin; EVPL: Envoplakin; FN1: Fibronectin; GRB2: Growth factor receptor-bound 
protein 2; HNF1A: Hepatocyte nuclear factor 1-alpha; HPR: Haptoglobin-related protein; HSPA1A: Heat shock 70 kDa protein 1A; ITGA2: Integrin alpha-2; ITGA2B: 
Integrin alpha-Ⅱb; ITGA5: Integrin alpha-5; ITGAM: Integrin alpha-M; ITGB1: Integrin beta-1; ITGB2: Integrin beta-2; ITGB3: Integrin beta-3; LGALS1: Galectin-1; MAX: 
Protein max; MMP8: Neutrophil collagenase; MYC: Myc proto-oncogene protein; MYOC: Myocilin; POLD1: DNA polymerase delta catalytic subunit; PRSS1: Trypsin-1; 
SERPINF2: Alpha-2-antiplasmin; SHC1: SHC-transforming protein 1; TAF1: Transcription initiation factor TFIID subunit 1; TANK: TRAF family member-associated NF-
kappa-B activator; TGFBR1: TGF-beta receptor type-1; TNR: Tenascin-R; TRB@: T-cell receptor beta; TRIM63: E3 ubiquitin-protein ligase TRIM63; UGCGL1: UDP-
glucose:glycoprotein glucosyltransferase 1; VCAN: Versican core protein; VIM: Vimentin; AFM: Afamin; CD5L: CD5 antigen-like; CLCA1: Calcium-activated chloride 
channel regulator 1; CLEC14A: C-type lectin domain family 14 member A; DPEP1: Dipeptidase; FAM151A: Protein FAM151A; FAM3C: Protein FAM3C; GGT6: Gamma-
glutamyltransferase 6; GLB1: Beta-galactosidase; HAVCR2: Hepatitis A virus cellular receptor 2; KIAA0753: Uncharacterized protein KIAA0753; LGALS9B: Galectin-9B; 
MBL: Mannose-binding lectin; MMP-7: Matrilysin; MRC2: C-type mannose receptor 2; PGA4: Pepsin A-4; PI16: Peptidase inhibitor 16; RTN4RL2: Reticulon-4 receptor-
like 2; SERPINA2P: Putative alpha-1-antitrypsin-related protein; SHISA5: Protein shisa-5; VASN: Vasorin.
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Some of these goals may be not too far away on 
the horizon. Currently, a few ongoing studies might 
address some of the discussed issues (Table 2). All 
studies are prospective, observational cohort studies 
and all except one collect samples in a longitudinal 
fashion. Results are expected in 2015 and 2016. These 
studies will hopefully clarify which role proteomic 
markers for rejection might have in the future care of 
kidney transplant patients. 
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